Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS:

* Histologically confirmed diagnosis of invasive breast cancer

  * Previously untreated disease
* Candidate for breast-conserving surgery, as defined by both of the following:

  * Clinical stage cT1-3, cN0-2 disease
  * Clinical stage M0 disease (bone scan, chest X-ray, and liver ultrasound required at screening to exclude metastatic disease)
* HER2-positive primary tumor, defined as meeting either of the following criteria:

  * IHC 3+
  * IHC 2+ and FISH positive (centralized confirmation)
* No inflammatory breast cancer or bilateral breast cancer

  * Patients who have been treated for cancer of the contralateral breast can be included if there is at least a 5 year time interval from last systemic treatment for breast cancer before randomization into this study
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* WHO performance status 0-1
* Menopausal status not specified
* WBC ≥ 3.5 x 10\^9/L
* ANC ≥ 1.5 x 10\^9/L
* Platelet count ≥ 100 x 10\^9/L
* Hb ≥ 10 g/dL
* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
* Serum transaminases activity ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
* FEV \> 55% by MUGA or ECHO
* Spirometry and DLCO \> 50% of normal
* O\_2 saturation \> 88% at rest on room air
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No known hypersensitivity to everolimus, sirolimus, trastuzumab (Herceptin®), or lactulose
* No hypercholesterolemia/hypertriglyceridemia ≥ grade 3

  * No hypercholesterolemia/hypertriglyceridemia ≥ grade 2 with history of coronary artery disease (despite lipid-lowering treatment if given)
* No uncontrolled infection
* No other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including any of the following:

  * Uncontrolled hypertension
  * Congestive cardiac failure
  * Ventricular arrhythmias
  * Active ischemic heart disease
  * Myocardial infarction within the past year
  * Chronic liver or renal disease
  * Active gastrointestinal tract ulceration
  * Severely impaired lung function
* No known history of HIV seropositivity
* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
* Willing to participate in the biological investigations
* Not deprived of liberty or placed under guardianship
* Patients must be affiliated to a Social Security System

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* More than 30 days (from the screening visit) since prior other investigational drugs
* More than 5 days (from randomization) since prior and no concurrent strong inhibitors or inducers of the isoenzyme CYP3A, including any of the following

  * Rifabutin
  * Rifampicin
  * Clarithromycin
  * Ketoconazole
  * Itraconazole
  * Voriconazole
  * Ritonavir
  * Telithromycin
* No other concurrent anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy, or radiotherapy